Intervention Review

Erythropoietin or darbepoetin for patients with cancer

  1. Thomy Tonia1,
  2. Annette Mettler1,
  3. Nadège Robert2,
  4. Guido Schwarzer3,
  5. Jerome Seidenfeld4,
  6. Olaf Weingart5,
  7. Chris Hyde6,
  8. Andreas Engert7,
  9. Julia Bohlius1,*

Editorial Group: Cochrane Haematological Malignancies Group

Published Online: 12 DEC 2012

Assessed as up-to-date: 2 MAY 2012

DOI: 10.1002/14651858.CD003407.pub5


How to Cite

Tonia T, Mettler A, Robert N, Schwarzer G, Seidenfeld J, Weingart O, Hyde C, Engert A, Bohlius J. Erythropoietin or darbepoetin for patients with cancer. Cochrane Database of Systematic Reviews 2012, Issue 12. Art. No.: CD003407. DOI: 10.1002/14651858.CD003407.pub5.

Author Information

  1. 1

    University of Bern, Institute of Social and Preventive Medicine, Bern, Switzerland

  2. 2

    Kantonsspitalapotheke Winterthur, Pharmacy, Winterthur, Switzerland

  3. 3

    Institute of Medical Biometry and Medical Informatics, University Medical Center Freiburg, German Cochrane Centre, Freiburg, Germany

  4. 4

    American Society of Clinical Oncology, Department of Quality and Guidelines, Alexandria, VA, USA

  5. 5

    Cologne, Germany

  6. 6

    University of Exeter Medical School, University of Exeter, Peninsula Technology Assessment Group (PenTAG), Exeter, UK

  7. 7

    University Hospital of Cologne, Cochrane Haematological Malignancies Group, Department I of Internal Medicine, Cologne, Germany

*Julia Bohlius, Institute of Social and Preventive Medicine, University of Bern, Bern, 3012, Switzerland. jbohlius@ispm.unibe.ch.

Publication History

  1. Publication Status: New search for studies and content updated (conclusions changed)
  2. Published Online: 12 DEC 2012

SEARCH

  1. Current Version

    Erythropoietin or darbepoetin for patients with cancer

    Thomy Tonia, Annette Mettler, Nadège Robert, Guido Schwarzer, Jerome Seidenfeld, Olaf Weingart, Chris Hyde, Andreas Engert and Julia Bohlius

    Version of Record online: 12 DEC 2012 | DOI: 10.1002/14651858.CD003407.pub5

Previous versions of this article and their online publication dates

  1. Version 4

    Erythropoietin or Darbepoetin for patients with cancer

    Julia Bohlius, Jayne Wilson, Jerome Seidenfeld, Margret Piper, Guido Schwarzer, Josie Sandercock, Sven Trelle, Olaf Weingart, Susan Bayliss, Susan Brunskill, Benjamin Djulbegovic, Charles Bennett, Simon Langensiepen, Chris Hyde and Andreas Engert

    Version of Record online: 19 JUL 2006 | DOI: 10.1002/14651858.CD003407.pub4

  2. Version 3

    Erythropoietin for patients with malignant disease

    J Bohlius, S Langensiepen, G Schwarzer, J Seidenfeld, M Piper, C Bennet and A Engert

    Version of Record online: 19 OCT 2005 | DOI: 10.1002/14651858.CD003407.pub3

  3. Version 2

    Erythropoietin for patients with malignant disease

    J Bohlius, S Langensiepen, G Schwarzer, J Seidenfeld, M Piper, C Bennet and A Engert

    Version of Record online: 19 JUL 2004 | DOI: 10.1002/14651858.CD003407.pub2

  4. Version 1

    Erythropoietin for patients with malignant disease

    S Langensiepen, J Bohlius, J Seidenfeld, M Piper, C Bennett, G Schwarzer and A Engert

    Version of Record online: 22 APR 2002 | DOI: 10.1002/14651858.CD003407